As of 2025-05-30, the Intrinsic Value of Chemomab Therapeutics Ltd (CMMB) is -3.51 USD. This CMMB valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.36 USD, the upside of Chemomab Therapeutics Ltd is -357.86%.
Based on its market price of 1.36 USD and our intrinsic valuation, Chemomab Therapeutics Ltd (CMMB) is overvalued by 357.86%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -3.51 - -3.51 | -3.51 | -357.86% |
| P/E | (13.46) - (12.77) | (13.40) | -1083.7% |
| DDM - Stable | (8.05) - (33.74) | (20.89) | -1633.6% |
| DDM - Multi | (0.28) - (0.91) | (0.43) | -131.5% |
| Market Cap (mil) | 25.98 |
| Beta | 1.41 |
| Outstanding shares (mil) | 19.07 |
| Enterprise Value (mil) | 17.65 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.99% |
| Cost of Debt | 5.00% |
| WACC | 5.83% |